Krystal Biotech (KRYS) Operating Expenses (2016 - 2026)

Krystal Biotech has reported Operating Expenses for 11 years, with the latest figure at $60.8 million in Q2 2026.

• Operating Expenses for Q2 2026 came in at $60.8 million, up 7.35% year-over-year; the trailing twelve-month figure through Jun 2026 was $242.7 million (up 10.48% YoY), and the FY2025 annual result was $227.8 million, up 1.36% from the prior year.
• Operating Expenses declined to $60.8 million in Q2 2026, from $62.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $62.8 million in Q4 2025 and troughed at $28.8 million in Q2 2022.
• A 5-year average of $49.0 million and a median of $51.1 million in 2022 frame the typical range for Operating Expenses.
• The widest annual swing landed in 2022, when Operating Expenses jumped 249.91%; it then fell 8.22% in 2025.
• A 5-year view of Operating Expenses shows it stood at $34.8 million in 2022, then rose by 11.86% to $38.9 million in 2023, then rose by 27.94% to $49.8 million in 2024, then climbed by 26.27% to $62.8 million in 2025, then dropped by 3.23% to $60.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $60.8 million in Q2 2026, $62.7 million in Q1 2026, and $62.8 million in Q4 2025.